help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HOFMANN, T.
Right arrow Articles by BOUCHER, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HOFMANN, T.
Right arrow Articles by BOUCHER, R. C.

Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, 1844-1849

Effects of Topically Delivered Benzamil and Amiloride on Nasal Potential Difference in Cystic Fibrosis

T. HOFMANN, M. J. STUTTS, A. ZIERSCH, C. RÜCKES, W. M. WEBER, M. R. KNOWLES, H. LINDEMANN, and R. C. BOUCHER

Cystic Fibrosis Working Group and Selbst. Funktionsbereich Allergologie und Pneumologie der Justus Liebig Universitäts-Kinderklinik, Giessen, Germany; and Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

The raised nasal transepithelial potential difference (PD) in cystic fibrosis (CF) reflects accelerated active transport of Na+, and is inhibited by topical administration of the Na+ channel blocker, amiloride. The aim of this study was to investigate the dose-effect and time course of topically administered Na+ conductance inhibitors to inhibit nasal PD, including benzamil, an analog of amiloride. We measured the magnitude of drug inhibition of Na+ transport [percent inhibition of baseline PD (Delta PD%)] and duration of inhibition of PD, defined as the time when drug inhibition of PD had recovered by 50% (effective time = ET50). Amiloride [10-3 M (n = 16), 3 × 10-3 M (n = 9), 6 × 10-3 M (n = 7), 10-2 M (n = 3)] or benzamil [1.7 × 10-3 M (n = 7), and 7 × 10-3 M (n = 5)] were administered to the nasal surface via an aerosol generated by a jet nebulizer and a nasal mask. The concentration-dependent magnitude (Delta PD%) of inhibition was similar for amiloride and benzamil (~ 67- 77%), whereas the duration of inhibition (ET50) was about two-and-a-half times longer after benzamil administration as compared with equivalent concentrations of amiloride [1.6 ± 0.06 versus 4.5 ± 0.6 h (ET50 ± SEM), at 6-7 × 10-3 M]. In vitro studies of cultured normal nasal epithelia demonstrated directly that benzamil induced an approximately 2-fold more prolonged inhibition of active Na+ transport than amiloride. These data suggest aerosolized benzamil is a candidate long-duration Na+ channel blocker for CF.




This article has been cited by other articles:


Home page
ChestHome page
S. H. Donaldson and R. C. Boucher
Sodium Channels and Cystic Fibrosis
Chest, November 1, 2007; 132(5): 1631 - 1636.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
S. M. Rowe, F. Accurso, and J. P. Clancy
Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials
Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society
  ATS State of the Art 2009